Cardiac Biomarkers and Early Detection of Cardiotoxicity

• Authors: Daniel Lenihan , Benjamin D. Humphreys
• Languages of publication: EN

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2016
• Volume: 6
• Issue: 3
• Pages: A97-99

Contributors

author

Daniel Lenihan

• Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee, United States

author

Benjamin D. Humphreys

• Washington University School of Medicine, St. Louis, Missouri, United States

References

• 1. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011; 123: 551-565.
• 2. Wang TJ, Wollert KC, Larson MG et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012; 126: 1596-1604.
• 3. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55: 213-220.
• 4. Cardinale D, Colombo A, Bacchiani G et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131: 1981-1988.
• 5. Curigliano G, Cardinale D, Dent S et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 2016; 66: 309-325.
• 6. Witteles RM. Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies. J Card Fail 2016; 22: 459-464.
• 7. Patel TV, Morgan JA, Demetri GD et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008;100: 282-284.
• 8. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010; 30: 591-601.
• 9. Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res 2009; 15: 5947-5949.
• 10. Rini BI, Melichar B, Ueda T et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013; 14: 1233-1242.
• 11. Berruti A, Fazio N, Ferrero A et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer 2014; 14: 184.

• Document Type: minireview